Amundi Has $106,000 Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Amundi lowered its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 21.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,360 shares of the biotechnology company’s stock after selling 1,431 shares during the period. Amundi’s holdings in Arrowhead Pharmaceuticals were worth $106,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. R Squared Ltd bought a new position in Arrowhead Pharmaceuticals in the fourth quarter worth approximately $38,000. Van ECK Associates Corp boosted its holdings in Arrowhead Pharmaceuticals by 72.3% in the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 1,250 shares in the last quarter. KBC Group NV boosted its holdings in Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock worth $98,000 after acquiring an additional 1,644 shares in the last quarter. Quantbot Technologies LP bought a new position in Arrowhead Pharmaceuticals in the third quarter worth approximately $149,000. Finally, First Citizens Bank & Trust Co. bought a new position in Arrowhead Pharmaceuticals in the fourth quarter worth approximately $205,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a report on Friday, December 20th. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. Royal Bank of Canada restated an “outperform” rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. B. Riley restated a “buy” rating and issued a $38.00 target price (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Finally, Piper Sandler dropped their target price on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $41.44.

Insiders Place Their Bets

In other news, CEO Christopher Richard Anzalone sold 51,425 shares of Arrowhead Pharmaceuticals stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $15.07, for a total value of $774,974.75. Following the completion of the transaction, the chief executive officer now directly owns 4,062,377 shares in the company, valued at approximately $61,220,021.39. The trade was a 1.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider James C. Hamilton sold 32,729 shares of Arrowhead Pharmaceuticals stock in a transaction on Monday, January 6th. The shares were sold at an average price of $19.82, for a total value of $648,688.78. Following the completion of the transaction, the insider now owns 272,122 shares of the company’s stock, valued at approximately $5,393,458.04. This trade represents a 10.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 301,730 shares of company stock valued at $5,352,844 over the last ninety days. 4.30% of the stock is currently owned by insiders.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ:ARWR opened at $14.80 on Friday. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. The business has a fifty day simple moving average of $18.58 and a two-hundred day simple moving average of $19.90. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $14.23 and a 1 year high of $30.41. The company has a market capitalization of $2.03 billion, a P/E ratio of -2.86 and a beta of 0.92.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). On average, analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.